Stories tagged “Biotech.”
30 stories
Insmed reported total revenues of $425.5 million, driven by a $309.2 million contribution from the commercial launch of BRINSUPRI. The company raised its fiscal 2026 revenue guidance for BRINSUPRI and increased its long-term combined peak sales estimate for three lead ass…
Alnylam Pharmaceuticals (ALNY) management reported Q2 2026 earnings, exceeding $1 billion in TTR franchise revenues for the first time. However, the company lowered its full-year product revenue guidance due to normalized second-line demand. AMVUTTRA is increasingly being…
The article compares the State Street Health Care Select Sector SPDR ETF (XLV) and the Invesco Nasdaq Biotechnology ETF (IBBQ), discussing their differences in terms of cost, size, and performance.
Montana has enacted a new "right to try" law allowing biotech companies to apply for approval to sell experimental drugs after preliminary testing. The law aims to create an experimental medical hub, but raises ethical concerns.
Cool Japan Fund Headed for the Deep Freeze
The Cool Japan Fund, a public-private entity established in 2013 to support the overseas expansion of Japanese contents and products, is facing massive losses exceeding 50 billion yen. The fund's flawed strategy and implementation have led to the failure of several ventur…
Throne Science, a startup that makes an AI-powered toilet camera to track gut health and hydration, has raised $10 million in a Series A round led by Will Ventures. The company was founded by CEO Scott Hickle and former Whoop co-founder and CTO John Capodilupo.
A Chinese university is investigating reports that a gene-editing trial caused the death of a six-year-old girl, which was not disclosed in the published research.
Unicycive Therapeutics (UNCY) is rated as a speculative Buy with a scenario-weighted $10 price target, implying ~75% upside. FDA's second CRL was solely due to unresolved manufacturing issues; efficacy and safety remain unchallenged.
Capricor Therapeutics' EVP, General Counsel, Karen Krasney, sold 24,000 shares after exercising 24,100 stock options. This move is part of a 10b5-1 trading plan, which doesn't necessarily indicate insider information. The company's stock has been down 30% year-to-date, bu…
NovoCure (NVCR) delivered a strong 2Q26 beat, raising full-year guidance to $710–$725 million and achieving positive adjusted EBITDA, signaling a credible path to profitability.
Scientists have developed a device that allows organs to be cooled to -4 °C (25 °F) without forming ice, enabling the preservation of kidneys for days before successful transplantation into pigs.
Farm Watt Innovations, an Indian biotech startup, has secured ₹32.5 Cr ($3.3 Mn) in funding co-led by IAN Alpha Fund and Rainmatter to expand its biomass collection network and develop bioenergy plants.
Science Corporation, a startup developing novel brain-computer interfaces (BCI), won approval from Europe's medical device regulator to begin selling a device that restores vision lost from age-related macular degeneration.
A US biotech firm, Axiom Biosciences, plans a primary listing in Hong Kong to raise at least US$200 million in 2027, developing AI-powered therapies for infant brain injuries.
Karyopharm Therapeutics markets Xpovio (selinexor) in multiple myeloma and is running trials in multiple myeloma, myelofibrosis, and endometrial cancer, with key clinical catalysts ahead.
Colossal Biosciences, a de-extinction startup, is reportedly in talks to raise new funding at a $20 billion to $30 billion valuation. The company has generated revenue over the last year and has spun out several startups.
Dyne Therapeutics receives FDA Priority Review for z-rostudirsen in DMD, with a potential U.S. launch in Q1 2027. The company demonstrates best-in-class dystrophin expression in registrational trials, targeting a $3.5bn market for exon 51 skipping DMD patients.
Quanterix is transitioning from persistent losses to a turnaround, driven by a new, highly experienced management team post-Akoya acquisition. The company targets cash flow breakeven in H2 2026, leveraging cost synergies, commercial execution, and a large installed base f…
Brain-Computer Interface Market Heats Up, Founder Charges Investors 5,000 Yuan/Hour for Meetings
China's brain-computer interface (BCI) industry is experiencing a massive boom, attracting significant capital and leading to soaring company valuations, with some founders even charging investors for meetings.
Stoke Therapeutics' lead asset, zorevunersen, for Dravet Syndrome has fully enrolled its Phase 3 EMPEROR trial, with top-line results anticipated in H2 2027.
Viking Therapeutics has started testing a new weight loss drug, VK3019, which targets the amylin pathway, a new approach in the weight loss market dominated by Eli Lilly and Novo Nordisk.
Revolution Medicines, a biotech company, aims to replace chemotherapy with target treatments. Its positive Phase 3 findings could pave the way towards its regulatory approval, drawing in big investors like Stanley Druckenmiller.
The Parnassus Growth Equity Fund made significant portfolio adjustments in Q2 2026, initiating new positions in Twist Bioscience and Lumentum, while exiting Insmed, Boston Scientific, Salesforce, and Brown & Brown.
A recent surge in billion-dollar seed rounds has led to speculation that the venture model has been rewritten, but data suggests that this is not the case. The author, Ellie McDonald, a principal at Bison Ventures, argues that large first rounds in biotech have produced a…
Mainland Chinese institutional fund managers have increased stakes in Hong Kong-listed biotechnology stocks, drawn by attractive valuations amid a surge in cross-border licensing deals.
Neko Health, a body-scanning and health assessment startup founded by Spotify's Daniel Ek, has raised a $700 million Series C. The company has developed proprietary body-scanning technology that it couples with bloodwork to assess a person's health.
Celcuity Inc. secured FDA approval for REVTORPYK, a pan-PI3K, mTORC1/2 inhibitor for 2nd-line PIK3CA wild-type HR+/HER2- advanced breast cancer. The company downgraded from Strong Buy to Buy due to phase 3 mutant cohort data underperforming prior results and rising compet…
OpenAI researcher Miles Wang is reportedly leaving to launch an AI drug discovery startup, seeking $200 million at a $2 billion valuation, with Lightspeed in talks to lead the round. Several other OpenAI researchers are expected to join the new venture.
Chinese Biotech Firm NNB Nutrition Secures Near $300M C+ Round Funding
Chinese biotech firm NNB Nutrition has secured near $300M C+ round funding, led by China Life Insurance and followed by existing shareholder Minghe Capital. The funding will be used for product research and development, new factory construction, and other purposes.
BridgeBio Pharma (BBIO) remains a 'Strong Buy' driven by regulatory approvals, robust pipeline progress, and significant commercial momentum for Attruby in ATTR-CM. The company has achieved U.S. and international approvals for acoramidis, with Q1 2026 U.S. net product rev…